On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASN Ended 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported...

PRESS RELEASE        Paris, 18 March 2026 – 5:45pm YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION 2025 RESULTS Positive net income in an unstable geopolitical and economic environmentTurnover1 of €156.1m, down -5.4% Operating EBITDA2 : €52.7m Group share of net profit: €1.7m, vs. €3.9m in 2024“Despite significant economic and geopolitical tensions in 2025, the TOUAX Group confirmed the resilience of its business model and its adaptability. Outside Europe, demand for mobile assets linked to transport infrastructure remains strong. With a diversified offer, long-term leasing contracts and a strong presence in various complementary business segments, the Group benefits from recurring revenue enabling it to face difficult economic conditions while limiting volatility. The strong momentum in management activity on...

LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) — LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for the year 2025. Twelve Months 2025 Financial and Business HighlightsTotal twelve-month revenues of $11.1 million Healthcare revenues of $10 million in 2025 Net income from operations of $326,000 Net Cash of $5.7 millionManagement Commentary “We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked David Houston, Chief Financial Officer, of LiveWorld. “While our revenues were down approximately 2% year-over-year we did improve our net income for the same period by over 376%. As we move into 2026, we will continue our investment in AI...

Q4 gross margins increased quarterly despite revenue dip2025 Revenue by Process Node and ApplicationsOn a technology basis, 87% of Alchip’s 2025 revenue came through process technologies at 7nm or smaller line widths. On an application basis, HPC accounted for 83% of Alchip’s 2025 revenue.Taipei, Taiwan, March 18, 2026 (GLOBE NEWSWIRE) — Alchip Technologies reported fourth‑quarter performance, with gross margin and net profit exceeding internal expectations. At the same time, the company reported a dip in 2025 revenue, citing limited production; but forecast a return to long-term growth in 2026. Alchip reported 2025 fourth quarter net income of $48 million, up 8.1 percent over third quarter 2025 net income of $44.3 million.  Fourth quarter 2025 revenue was $152.7 million, compared to fourth quarter 2024 revenue of $404.1...

2025 Net Loss of $5,025,000 ($1.51 loss per share) vs. Net Loss of $646,000 ($0.19 loss per share) in 2024 2025 EBITDA, As Adjusted, was a loss of $3,971,000 ($1.19 loss per share) vs. earnings of $159,000 ($0.05 per diluted share) in 2024 Fourth Quarter 2025 Net Loss of $708,000 ($0.21 loss per share) vs. Net Loss of $252,000 ($0.08 loss per share) in Prior Year Period Fourth Quarter 2025 EBITDA, As Adjusted, was a loss of $465,000 ($0.14 loss per share) vs. earnings of $383,000 ($0.11 per diluted share) in Prior Year Period Backlog at December 31, 2025 was approximately $12.2 million compared to approximately $12.0 million at December 31, 2024 HAUPPAUGE, N.Y., March 18, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the fourth quarter and the year ended December 31, 2025. Fourth...

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key HighlightsIn December 2025, the Company announced the results of an interim analysis of the Halneuron® Phase 2b trial. The independent statistical review committee...

Fourth quarter of 2025 revenue increased 70.2% year-over-year to $12.0 million, with record quarterly gross margin of 58.5% Net income from continuing operations of $2.0 million for 2025 fourth quarter Positive defense and commercial market demand is expected to support another strong year of revenue growth in 2026 ESCONDIDO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML), autonomy and sensor processing at the edge, reported results for the fourth quarter ended December 31, 2025. Fourth quarter and twelve-month comparisons are to the same year-ago periods unless otherwise noted. On December 30, 2025, the Company closed a definitive agreement to sell...

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the fourth quarter and full year ended December 31, 2025. “We are entering 2026 with a pivotal transaction that establishes...

U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, “Cingulate delivered on key inflection points throughout 2025...

MAYFIELD VILLAGE, OHIO, March 18, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended February 28, 2026:  February(millions, except per share amounts and ratios; unaudited)   2026       2025     ChangeNet premiums written $ 6,995     $ 6,684     5   %Net premiums earned $ 6,528     $ 6,036     8   %Net income $ 943     $ 928     2   %Per share available to common shareholders $ 1.61     $ 1.58     2   %Total pretax net realized gains (losses) on securities $ (5 )   $ (110 )   (95 ) %Combined ratio   85.7       82.6     3.1   pts.Average diluted equivalent common shares   586.8       587.6     0   %  February 28,(thousands; unaudited) 2026   2025   % ChangePolicies in Force          Personal Lines          Agency – auto 10,959   9,950   10Direct...